Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Cancer Metastatic
Sponsor: Pfizer